IFP Advisors’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-650
| Closed | -$21.1K | – | 3373 |
|
|
2024
Q1 | $21.1K | Hold |
650
| – | – | ﹤0.01% | 1940 |
|
|
2023
Q4 | $15.4K | Hold |
650
| – | – | ﹤0.01% | 2021 |
|
|
2023
Q3 | $9.69K | Hold |
650
| – | – | ﹤0.01% | 2266 |
|
|
2023
Q2 | $7.12K | Hold |
650
| – | – | ﹤0.01% | 2412 |
|
|
2023
Q1 | $8.24K | Sell |
650
-1,000
| -61% | -$8.01K | ﹤0.01% | 2374 |
|
|
2022
Q4 | $21K | Hold |
1,650
| – | – | ﹤0.01% | 2859 |
|
|
2022
Q3 | $21K | Hold |
1,650
| – | – | ﹤0.01% | 3057 |
|
|
2022
Q2 | $21K | Hold |
1,650
| – | – | ﹤0.01% | 2815 |
|
|
2022
Q1 | $21K | Buy |
1,650
+1,000
| +154% | +$3.15K | ﹤0.01% | 2815 |
|
|
2021
Q4 | $2K | Hold |
650
| – | – | ﹤0.01% | 2870 |
|
|
2021
Q3 | $2K | Hold |
650
| – | – | ﹤0.01% | 2917 |
|
|
2021
Q2 | $3K | Hold |
650
| – | – | ﹤0.01% | 2684 |
|
|
2021
Q1 | $3K | Hold |
650
| – | – | ﹤0.01% | 2605 |
|
|
2020
Q4 | $4K | Hold |
650
| – | – | ﹤0.01% | 2447 |
|
|
2020
Q3 | $5K | Buy |
+650
| New | +$3.48K | ﹤0.01% | 2205 |
|
|
2019
Q1 | – | Sell |
-1,020
| Closed | -$8K | – | 3575 |
|
|
2018
Q4 | $8K | Hold |
1,020
| – | – | ﹤0.01% | 2637 |
|
|
2018
Q3 | $11K | Buy |
1,020
+20
| +2% | +$248 | ﹤0.01% | 2826 |
|
|
2018
Q2 | $13K | Sell |
1,000
-4,000
| -80% | -$50.1K | ﹤0.01% | 2758 |
|
|
2018
Q1 | $46K | Hold |
5,000
| – | – | ﹤0.01% | 1870 |
|
|
2017
Q4 | $46K | Hold |
5,000
| – | – | ﹤0.01% | 1888 |
|
|
2017
Q3 | $40K | Buy |
5,000
+1,000
| +25% | +$6.76K | ﹤0.01% | 2139 |
|
|
2017
Q2 | $23K | Buy |
+4,000
| New | +$17K | ﹤0.01% | 2507 |
|
IFP Advisors's CBAY Position: Q2 2024 in Review
IFP Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2024, closing a stake of 650 shares — an estimated $21.1K sold.
IFP Advisors first reported a position in CBAY in Q2 2017 and held it in 22 quarters. The position peaked at $46K in Q1 2018. 0 funds tracked by Wall St. Rank hold CBAY as of Q2 2024.
- IFP Advisors reported no remaining Cymabay Therapeutics position as of Q2 2024 after selling out during the quarter.
- IFP Advisors sold 650 Cymabay Therapeutics shares in Q2 2024, an estimated $21.1K.
- IFP Advisors first reported a position in Cymabay Therapeutics in Q2 2017 and held it in 22 quarters.
- IFP Advisors's Cymabay Therapeutics position peaked at $46K in Q1 2018.
- 0 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2024.
Based on IFP Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.